Clinical Research Study| Volume 131, ISSUE 4, P442.e9-442.e12, April 2018

Inferior Vena Cava Filters in Patients with Acute Pulmonary Embolism and Cancer

Published:November 10, 2017DOI:



      Administrative data have shown a lower mortality in hospitalized patients with pulmonary embolism and cancer who receive a vena cava filter. In the absence of a randomized controlled trial of vena cava filters in such patients, further investigation is necessary. Therefore, we performed this investigation using administrative data from a different database than used previously, and we investigate patients hospitalized in more recent years.


      We analyzed administrative data from the Premier Healthcare Database, 2010-2014, in patients hospitalized with pulmonary embolism and solid malignant tumors. Patients were identified on the basis of International Classification of Disease, Ninth Revision, Clinical Modification codes.


      Patients aged >60 years had a lower in-hospital all-cause mortality with vena cava filters than those who did not have filters, 346 of 4648 (7.4%) compared with 2216 of 19,847 (11.2%) (P < .0001) (relative risk 0.67). Among patients aged >60 years who received an inferior vena cava, all-cause mortality within 3 months was 704 of 4648 (15.1%), compared with 3444 of 19,847 (17.4%) among those who did not receive a filter (P < .0001) (relative risk 0.86).


      Elderly patients with pulmonary embolism and cancer may be a special population in whom inferior vena cava filters reduce in-hospital and 3-month all-cause mortality. Further investigation is needed, particularly in younger patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Arklel Y.S.
        Thrombosis and cancer.
        Semin Oncol. 2000; 27: 362-374
        • Donati M.B.
        Cancer and thrombosis.
        Haemostasis. 1994; 24: 128-131
        • Stein P.D.
        • Beemath A.
        • Meyers F.A.
        • et al.
        Incidence of venous thromboembolism in patients hospitalized with cancer.
        Am J Med. 2006; 119: 60-68
        • Cohen A.T.
        • Katholing A.
        • Rietbrock S.
        • et al.
        Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
        Thromb Haemost. 2017; 117: 57-65
        • Stein P.D.
        • Matta F.
        • Sabra M.J.
        Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism.
        Am J Med. 2013; 126: 819-824
        • Goldhaber S.Z.
        Requiem for liberalizing indications for vena caval filters?.
        Circulation. 2016; 133: 1992-1994
        • Mismetti P.
        • Laporte S.
        • Pellerin O.
        • et al.
        Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.
        JAMA. 2015; 313: 1627-1635
        • Stein P.D.
        • Matta F.
        Case fatality rate with pulmonary embolectomy for acute pulmonary embolism.
        Am J Med. 2012; 125: 471-477
        • Stein P.D.
        • Matta F.
        • Keyes D.C.
        • Willyerd G.L.
        Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism.
        Am J Med. 2012; 125: 478-484
        • Cohen J.
        Statistical Power Analysis for the Behavioral Sciences.
        Lawrence Erlbaum Associates, Hillsdale, NJ1988: 181
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • et al.
        Antithrombotic therapy for VTE disease: chest guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Lévesque L.E.
        • Hanley J.A.
        • Kezouh A.
        • Suissa S.
        Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.
        BMJ. 2010; 340: b5087